PDF(Pubmed)
Abstract：
Marburg virus (MARV) is a highly contagious and virulent agent belonging to Filoviridae family. MARV causes severe hemorrhagic fever in humans and non-human primates. Owing to its highly virulent nature, preventive approaches are promising for its control. There is currently no approved drug or vaccine against MARV, and management mainly involves supportive care to treat symptoms and prevent complications. Our aim was to design a novel multi-epitope vaccine (MEV) against MARV using immunoinformatics studies. In this study, various proteins (VP35, VP40 and glycoprotein precursor) were used and potential epitopes were selected. CTL and HTL epitopes covered 79.44% and 70.55% of the global population, respectively. The designed MEV construct was stable and expressed in Escherichia coli (E. coli) host. The physicochemical properties were also acceptable. MARV MEV candidate could predict comprehensive immune responses such as those of humoral and cellular in silico. Additionally, efficient interaction to toll-like receptor 3 (TLR3) and its agonist (β-defensin) was predicted. There is a need for validation of these results using further in vitro and in vivo studies.
摘要：
马尔堡病毒（MARV）是一种高度传染性和毒性的病原体，属于丝状病毒科。MARV在人类和非人类灵长类动物中引起严重的出血热。由于其剧毒性质,预防性方法对其控制是有希望的。目前没有批准的针对MARV的药物或疫苗，管理主要包括支持性护理，以治疗症状和预防并发症。我们的目的是使用免疫信息学研究设计一种针对MARV的新型多表位疫苗（MEV）。在这项研究中,使用各种蛋白质(VP35、VP40和糖蛋白前体)并选择潜在的表位。CTL和HTL表位覆盖了79.44%和70.55%的全球人口，分别。设计的MEV构建体稳定并在大肠杆菌中表达(E.大肠杆菌)宿主。物理化学性质也是可接受的。MARVMEV候选物可以预测综合免疫反应，例如体液和细胞的免疫反应。此外,预测了与toll样受体3（TLR3）及其激动剂（β-防御素）的有效相互作用。需要使用进一步的体外和体内研究来验证这些结果。
